Alexion Pharmaceuticals, Inc.’s Post

Find our Global research director @ADA2024 Orlando and discuss all about metabolic and endocrine clinical trials, these is what AGA Clinical Trials is best in the world of clinical trials. #clinicalresearch #clinicaltrials #obesity #diabetes

Find our Global research director @ADA2024 Orlando and discuss all about metabolic and endocrine clinical trials, these is what AGA Clinical Trials is best in the world of clinical trials. #clinicalresearch #clinicaltrials #obesity #diabetes

FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma. This application was granted priority review, breakthrough designation and orphan drug designation. Day One Biopharmaceuticals 👏 More detail in the caption below

Tecarfarin has been evaluated in 11 human clinical trials in more than a thousand individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials that have conducted thus far, tecarfarin has generally been well-tolerated in both healthy adult patients and patients with chronic kidney disease.   We have established that tecarfarin has a similar Mechanism of Action to that of warfarin, while also showing that tecarfarin’s elimination from the body was not affected by severe kidney dysfunction.   We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation.   #cadrenal #tecarfarin #nasdaq #cvkd Cadrenal Therapeutics, Inc.

Today we announced the extension of our collaboration with Acumen to to enable the potential future commercial launch of sabirnetug (ACU193). Acumen is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta (Aβ) oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patients. The extended collaboration builds upon an existing successful relationship in which we provide drug substance manufacturing for the Phase 2 clinical supply of sabirnetug. Read more about our extended collaboration here: https://lnkd.in/dtWUP3uY #AHealthierWorld #PharmaceuticalManufacturing #DrugProduct #Alzheimers

Global #Bispecific #Antibody #Therapeutics #Contract Market: By Indication (Cancer, CNS Conditions, Autoinflammatory and Autoimmune Diseases, Infectious Diseases, Others), By Route of Administration (Intravenous, Subcutaneous, Others), By End-use (Pharmaceutical Companies, Biopharmaceutical Companies, Others), and Region – Cumulative Growth Opportunities Analysis, Size, Share, Trends, and Industry Forecast Till 2030. By:Analytical Market Research Read More Info:https://lnkd.in/dAF6Qqvc Key Players: Lonza; Roche's; Creative Biolabs; AbbVie; Amgen; The Janssen Pharmaceutical Companies of Johnson & Johnson; Johnson & Johnson; IQVIA; WuXi Biologics; Sino Biological, Inc. #marketgrowth #marketshare #marketsize #marketdemands #marketforecast #marketstretargy #marketanalysis #markettrends #market

#Lysosomal_Storage_Diseases_Therapeutics Market Share Expected Huge Growth during 2023-2032 https://lnkd.in/d6fk-3XH The factors that are driving the #global LSD #market are the increasing prevalence of #LSDs and growing awareness about LSDs. The other significant factors that are boosting the #market include increasing #research and #development activities by key #market players to find out an innovative solution for rare #diseases and increased product approvals. Shire Pfizer Pfizer Malaysia Sanofi BioMarin Pharmaceutical Inc. Actelion (now Janssen Pulmonary Hypertension) RAPTOR PHARMACEUTICAL INC Protalix Biotherapeutics Quest Diagnostics Quest Diagnostics Oncology Amicus Therapeutics

#Pfizer announced yesterday that it is voluntarily withdrawing all lots of #OXBRYTA® (#voxelotor) for the treatment of #sickle cell disease (#SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw OXBRYTA from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings. This comes after 2 year of Pfizer’s acquisition of Global Blood Therapeutics, the mother company of OXYBRYTA for $ 5.4 billion. In 2019, Global Blood Therapeutics won approval in the U.S. for Oxbryta. Adding Global Blood Therapeutics would bolster Pfizer's rare-diseases business and help it realize a longtime goal of selling drugs to treat sickle cell #rarediseaes #clinicaltrials

𝐙𝐲𝐕𝐞𝐫𝐬𝐚 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐏𝐡𝐚𝐬𝐞 𝟐𝐚 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐃𝐢𝐚𝐛𝐞𝐭𝐢𝐜 𝐊𝐢𝐝𝐧𝐞𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭" ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) ZyVersa Therapeutics Inc., a clinical-stage biopharmaceutical company, announces Institutional Review Board (IRB) approval for the Phase 2a clinical trial protocol to assess the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease patients. The trial is set to commence in the first half of 2024. This milestone marks ZyVersa's first human trial for VAR 200, aiming to validate promising preclinical results across multiple animal models of kidney disease. Preclinical data demonstrated VAR 200's ability to: Lower cholesterol and lipid levels in the kidneys. Protect against kidney injury and fibrosis. Reduce proteinuria. Stephen C. Glover Steve Glover, ZyVersa’s Co-founder, Chairman, CEO, and President, highlights the significance of addressing kidney disease progression, affecting over 35 million adults in the U.S. annually. VAR 200 holds potential in mitigating kidney injury and slowing disease progression. #Nephrology #RenalHealth #ChronicKidneyDisease #DrugDevelopment #KidneyDiseaseTreatment #DiabeticKidneyDisease

This week in biopharma, Roche laid out big plans, Rivus Pharmaceuticals touted promising heart failure data for its obesity asset, Eli Lilly and Company rose to meet manufacturing goals and FirstWord Group's data doyenne charted third-quarter dealmaking. Get up to speed with Friday Five https://lnkd.in/e8cPbQeN Regor Therapeutics Group Kezar Life Sciences UCB Biogen Novartis Bristol Myers Squibb Novo Nordisk Morphic Therapeutic Gilead Sciences #obesity #breastcancer #glp1 #weightloss #musclepreservation #cdkinhibitors #MandA #lungcancer #lupus #Gazyva #FDA #EMA #Lunsumio #HFpEF #Mounjaro #Zepbound #tirzepatide #HU6 #Ozempic #Wegovy #semaglutide #biopharma #biopharmanews #pharma #pharmanews #fridayfive #weeklywrapup #drugdevelopment #clinicalresearch #regulatoryaffairs